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Introduction
The purpose of this 1-day public workshop was to provide a 
forum to discuss the clinical development of intravenous fat 
emulsion (IVFE) products. This included the discussion of key 
issues in clinical trial design, including efficacy and safety out-
come measures that would support the approval of these new 
IVFE products. This public workshop was the collaborative 
effort of A.S.P.E.N. and the FDA. Initial discussion at 
A.S.P.E.N. came from Dr Vince Vanek, the lead author of the 
IVFE novel nutrient position paper published in Nutrition in 
Clinical Practice and then from the A.S.P.E.N. Corporate 
Scientific Advisory Council chaired by Dr Daniel Teitelbaum. 
The goal was to bring regulatory bodies, clinicians, research-
ers, and industry together on behalf of our patients, with the 
ultimate goal of bringing new and safer IVFE products into the 
U.S. market. This proceedings paper is comprised of abbrevi-
ated abstracts from each speaker. The abstracts are vignettes of 
what was presented during the workshop. Neither the presenta-
tions nor the abstracts represent a consensus for future devel-
opment of these IVFE products. The IVFE workshop laid the 
foundation for further discussions and actions regarding the 
development of IVFE products. Critical next steps for IVFE 
experts and stakeholders to consider include the identification 
of 1) evidence-based and clinically meaningful efficacy and 
safety endpoints for clinical trials and 2) populations to be 
studied. A full transcription of the public workshop can be 
accessed at http://www.regulations.gov/#!documentDetail;D= 
FDA-2013-N-0001-0088. To increase clarity, frequently used 
abbreviations can be found in Table 1. Please note: Some bib-
liography lists are numbered citations in the text, while others 
are further reading lists.
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Welcome
Donna Griebel
On behalf of FDA, I would like to welcome you all to today’s 
meeting. I want to extend a very sincere thanks to A.S.P.E.N. 
for their critical role in bringing everybody together for this 
meeting and facilitating making this meeting happen. It 
wouldn’t have happened without them so we are very, very 
grateful. I would also like to thank the members of the steering 
committee who helped develop the agenda for today’s meeting 
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and worked together over the last few months with the mem-
bers of the FDA to create today’s agenda. The steering commit-
tee members included representatives from industry, from 
academia, professional societies, patients, and government 
(both FDA and NIH).
It’s been many years since the first lipid emulsion products 
were approved, and we have limited availability in terms of range 
of lipid emulsion products on the market, as you all are aware. 
Over those decades, the concept and the framework for evidence-
based medicine has evolved and is far removed today from where 
it was back in the days when the emulsion products were first 
approved. FDA is a public health organization and science-based, 
and we work within a framework of laws and regulations that tell 
us what we can and cannot do when we evaluate drugs for 
marketing applications. As we’ve looked at these new marketing 
applications in the context of today’s scientific world, we must 
ask whether it’s enough just to answer the question, “For this bag 
of product that will be infused into a patient, is it enough to say, 
well, it has calories and fatty acids in it?” Is that enough or is 
there more that we need to know to be responsible to our patients 
and to future caregivers? Are there additional questions that we 
need to answer? As science has evolved, so have the laws and 
regulations. There are over time newer methods available to the 
FDA to facilitate answering some of these questions in order to 
get products to the market expeditiously, and we can have some 
discussion of that as it comes up in today’s meeting.
Overall, I would like to stress that today’s meeting is 
intended to be a dialogue. It’s not just a dialogue between the 
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FDA and you; it’s a dialogue that we at the FDA want to hear 
amongst all of you, so there’s going to be open microphones. 
We want to hear what the audience has to say, the questions, 
answers, and dialogue that happen between the moderators, 
speakers, and the members of the audience. For this reason, we 
strongly urge everybody to participate because what the FDA 
needs to hear is the discussion and its content.
I just want to reinforce that the patients are the chief stake-
holders, and those patients include both adults and children. 
We hope that today’s discussion will incorporate points that 
address the full population that benefit from these products.
Background/Overview
Utilization of IVFE Therapy in the United 
States
Peggi Guenter
This presentation is a brief history and overview of utilization 
of IVFE in context of PN use in the United States. All the way 
back to 1667, clinicians have been giving parenteral nutrition 
to patients through peripheral veins, and undoubtedly, there 
were some septic complications.1 Not until clinicians were 
able to safely catheterize large vessels, were they able to give 
concentrated dextrose and protein, and that happened in the 
1960s in the United States.1 At that time, Drs Dudrick, Wilmore, 
Vars, and Rhoads reported on a neonate with intestinal atresia 
who was able to be fed intravenously with dextrose and protein 
hydrolysate for about 30 weeks, during which time she grew 
and developed normally.2
From the 1920s to the 1960s, multiple types of fat sources 
were used. There was one commercial product, Lipomul®, a 
cottonseed oil–based product that was withdrawn from the 
market due to a high incidence of adverse events. In the early 
1960s, Swedish scientists developed successful fat prepara-
tion.3 In the United States from the 1960s to the mid-1970s, PN 
was IV fat emulsion–free because there was no approved IVFE 
in this country until the mid-1970s.
In early years, IVFE was used primarily to prevent essential 
fatty acid deficiency, and a typical dose for adults was 50 g of 
fat twice weekly and 0.5 g per kilogram per day for pediatrics. 
The trend in the 1980s to the 1990s was to use fat emulsion, 
often daily with administration of about 15%–30% of calories 
as fat.
In the United States, IVFE is used in a variety of ways. It is 
administered daily or 2–3 days weekly as a component of a 
total nutrient add mixture or infused separately from the base 
PN solution. IVFEs are also used intermittently as a source of 
essential fatty acids and not as an energy source in some indi-
viduals, including in patients with short bowel syndrome, as 
they are weaned from PN during intestinal rehabilitation and 
transition to oral diet, or in other types of patients transitioning 
to enteral nutrition. PN is given in many settings: home care, 
alternate care settings such as skilled nursing facilities and 
long-term acute care hospitals, and in acute care hospitals.
In terms of home care, in 1986 to the mid-1990s, there was 
the OASIS registry which was a combined Oley Foundation 
and A.S.P.E.N. project.4 This registry of home PN patients, 
reported in 1986 and 1987, consisted of approximately 15,000–
20,000 patients on home PN. We do not have any recent data 
nationwide but have started the A.S.P.E.N. SustainTM registry 
and have data on 1200 patients in the last 2 years. The average 
IVFE dose for those patients is 67 g of fat per day for adults 
and about 10 g for pediatrics.
There are few historical data on the use of IVFE in acute 
care hospitals. One study reported in 1984 that there were 
550,000 hospitalized patients receiving PN for an average of 
about 20 days.5,6 The early 1980s was probably the height of 
PN utilization in the United States. After that, there was pro-
spective payment and patients had shorter hospital stays with 
shifting certain diagnoses to use enteral instead of parenteral 
nutrition. Since then, there are more reliable data. Beginning in 
1993, the Agency for Healthcare Research and Quality 
(AHRQ) has published data through the Healthcare Utilization 
Project (HCUP), which has the National Inpatient Survey 
data.7 From this, PN utilization over time can be tracked. These 
data are pulled through ICD-9 procedure coding, and not per 
patient day or per patient, but by hospital stay or discharges. In 
1993, there were 150,000 hospital stays where patients received 
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PN, and this number increased and at least doubled over time 
until 2010 when there were about 370,000 patients receiving 
PN per year.7
Interestingly enough, the latest HCUP data are from 2011, 
where there has been a decrease in PN usage, and our suspicion 
is that that’s related to nutritional drug shortages. With so many 
products in the United States that are unavailable, providers are 
making hard decisions about how much PN they are prescrib-
ing. When you take this utilization data and normalize it per 
total discharges, you find that that trend is very similar, that 
there still is an increase, until the downturn in 2011. In looking 
at the 2011 statistics, in terms of patient characteristics, there 
are approximately 350,000 patients who receive PN, about 
one-third are under the age of 1 and about another third are 
over the age of 65 years. In terms of payer, Medicare is approx-
imately a third, private insurance a third, and Medicaid approx-
imately 25.0%, with the rest made up of uninsured or self-pay 
types of patients.7 Since 1993, the use of PN and hence IV fat 
emulsion is on the rise with high use in both neonates and older 
adults. The use in alternate healthcare settings, such as long-
term care and home care, is really unmeasured and difficult 
data to obtain. There is a need to look at these patterns and 
patient populations to help design clinical trials.
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Patient Perspective
Randall C. O’Reilly
To begin, I will share the story of my son, who was born with 20 
cm of functional short bowel due to very long-segment 
Hirschsprung’s disease. He has been on PN his entire life and 
developed PN-associated liver disease (PNALD) within his first 
months of life, experiencing total bilirubin levels as high as 20 
mg/dL and level 4 cirrhosis. After 6 months we were able get him 
started on fish oil IVFE (Omegaven®) instead of soybean IVFE 
(IntraLipid®), and his condition improved dramatically. He is 
now 7 years old and thriving. At a more objective level, I will 
present data from a patient survey I conducted with 71 cases of 
soybean IVFE users and 28 fish oil IVFE users, showing that my 
son’s experience is typical; there were over 50% of soybean 
IVFE patients who experienced PNALD, with a mean total bili-
rubin level of 9 mg/dL, and these symptoms were reversed in the 
28 fish oil IVFE patients, who experienced 0% negative side 
effects, and had mean total bilirubin levels of 0.22 mg/dL. I 
would argue that from the patient perspective, we already have 
extremely compelling data now that merits approval of fish oil 
IVFE and other IVFEs that include something other than pure 
soybean oil. The survey respondents overwhelmingly selected 
“strongly agree” to the statement that the FDA should aggres-
sively pursue approval of alternative IVFE formulations, and also 
responded with a mean “unsafe” opinion of the pure soy-oil 
based formulations that are currently available. IVFEs are, funda-
mentally, a food product providing essential nutrition; the only 
sense in which they are a drug is in the IV delivery, so the FDA’s 
evaluation could be focused on ensuring proper emulsification 
and sterilization, while recognizing that people need to have 
options in what kind of nutrition works best for them. This could 
establish a lower standard of evidence required for approval: the 
standard of noninferiority, which given the extensive experience 
with alternative formulations in Europe, it would seem, could be 
made immediately, and would likely be greeted with consider-
able enthusiasm from the patient community. We are already 
heartened by the rapid approval of a new olive oil–soybean oil 
based IVFE (Clinolipid®) and are optimistic that this is a sign of 
further approvals to come in short order. Many impassioned 
patient comments from the survey are included, imploring the 
FDA to find a way forward toward approval of alternatives to 
soybean IVFE in one way or another. Finally, as a footnote, based 
on the presentations at this meeting, my son Max is now on 50% 
fish oil–based IVFE and 50% soy-based IVFE, at a total of 2 g/
kg/d (instead of 1 g/kg/d of just fish oil–based), and in addition to 
the pure caloric benefits, his immune function seems stronger and 
his water transport (eg, dry skin) is markedly improved. This is 
one more data point in support of the notion that a more balanced 
approach to IVFE formulations may be best.
FDA Regulatory Framework
Karyn L. Berry
The Food and Drug Administration (FDA) is bound by various 
laws and regulations which provide the regulatory framework 
for its operations and decision making in approval of drugs. In 
1938, the Federal Food, Drug and Cosmetic Act (FD&C Act) 
was passed by Congress. It required drug manufacturers to 
demonstrate that their products were safe.
In 1962, Congress amended the act (Kefauver-Harris 
Amendment) to require manufacturers to demonstrate “sub-
stantial evidence of effectiveness” of a drug prior to marketing 
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approval. This law specifies that this evidence must be derived 
from adequate and well-controlled clinical investigations. An 
adequate and well-controlled study is defined as a design that 
permits a valid comparison with a control to provide a quanti-
tative assessment of drug effect. The study should be designed 
well enough so as to be able to distinguish the effect of a drug 
from other influences, such as spontaneous change, placebo 
effect, or biased observations.
Major elements of an adequate and well-controlled trial 
include 1) clear statement of objective, 2) valid comparison 
with a control to provide a quantitative assessment of drug 
effect, 3) method of selection of subjects provides an adequate 
assurance that they have the disease or condition being studied, 
4) method of assigning subjects to treatment and control groups 
that minimizes bias, 5) adequate measures are taken to mini-
mize bias on the part of subjects, observers, and analysts of the 
data, 6) well-defined and reliable outcome measures, and 7) 
analyses of the results that are adequate to assess the effects of 
the drug.
Endpoint assessment is a critical component of a well-con-
ducted clinical. Clinical endpoints directly measure a therapeu-
tic effect of a drug: an effect on how a patient feels (eg, 
symptom relief), functions (eg, improved mobility), or sur-
vives. A surrogate endpoint, on the other hand, predicts a clini-
cal benefit. It does not directly describe how a patient feels, 
functions, or survives as a result of treatment. Drug approvals 
may be based on established surrogate endpoints, such as 
improvements in blood pressure.
The accelerated approval regulations, implemented in 
1992, allow use of surrogate endpoints reasonably likely to 
predict clinical benefit for approval of drugs or biological 
products that are intended to treat serious or life-threatening 
diseases, and either that demonstrate an improvement over 
available therapy or provide therapy where none exists. The 
surrogate’s likelihood of predicting clinical benefit may be 
based on epidemiologic, therapeutic, pathophysiologic, or 
other evidence. Such surrogates are less well established than 
surrogates that have been used to support regular approval, 
such as blood pressure. A drug is approved under the acceler-
ated approval regulations on the condition that the manufac-
turer conducts clinical studies to verify and describe the actual 
clinical benefit.
Safety regulations apply to both before and after drug 
approval. Drug manufacturers are required to submit evidence 
of a drug’s safety prior to approval. Safety surveillance contin-
ues after drug approval (postmarketing surveillance). The FDA 
Amendments Act (FDAAA) of 2007 includes provisions to 
address drug safety. A section of the Act authorizes the FDA to 
require postmarketing studies and clinical trials at the time of 
approval, or after approval, if the FDA becomes aware of new 
safety information (eg, data about a serious risk or an unex-
pected serious risk associated with use of the drug).
As the development of intravenous fat emulsions (IVFEs) 
in the United States moves forward, there are a number of 
challenges. IVFEs provide nutrition and calories, but recent 
literature has purported biochemical-based benefits, such as a 
decreased proinflammatory response, when the amount of ω-6 
fatty acids in an IVFE is decreased and the amount of ω-3 fatty 
acids is increased. However, data supporting actual clinical 
benefits that are linked to these purported effects of newer 
IVFEs are limited. The goal of the workshop is to focus on the 
clinical development of IVFEs. This will include a discussion 
of 1) characteristics of clinical benefits related to IVFEs other 
than their being a source of calories/energy and 2) characteris-
tics of adequate and well-controlled trials that would establish 
these additional clinical benefits.
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Clinical Overview of IVFE
Currently Available IVFEs (U.S. and 
International)
Properties of the Fatty Acid Components of 
Intravenous Fat Emulsions
Richard J. Deckelbaum
The fatty acid components of lipid emulsion triglycerides have 
marked effects on their blood clearance, intracellular metabo-
lism, and biological endpoints. While IV lipid emulsions are 
similar in size and structure to postprandial chylomicrons, in 
addition to triglyceride, emulsions contain excess phospholip-
ids in the form of liposomes which affect their clearance from 
blood. Overall, blood clearance pathways of IV lipid emul-
sions are similar to chylomicrons. Emulsions are hydrolyzed in 
blood by lipoprotein lipase, followed by uptake of released 
fatty acids and remnant particles by liver and extrahepatic tis-
sues. Different than chylomicrons, the most commonly used 
lipid emulsion worldwide, made from soy oil, is much richer in 
ω-6 linoleic acid (55% of total fatty acids by weight) and con-
tains lower levels of other ω-6 and ω-3 unsaturated fatty acids 
compared with chylomicrons. Because of concerns related to 
“linoleic acid overload,” new lipid emulsions containing dif-
ferent fatty acids have been introduced. About 3 decades ago, 
MCT-containing emulsions were introduced to replace ~50% 
of the soy oil in IV lipid emulsions. More recently, emulsions 
containing fish oils have been introduced, as well as emulsions 
containing olive oil.
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Because of the higher solubility of MCT at the emulsion 
phospholipid water interface, MCT-containing emulsions are 
cleared much faster and efficiently in both in vitro systems as 
well as in vivo human studies. Fatty acids have marked effects 
on membrane structure and function, production and actions of 
cytokines and other immune factors, coagulation, vascular 
resistance, cell metabolism and signaling, as well as gene regu-
lation. Thus, it important to understand the different biological 
effects of emulsion triglyceride fatty acids. Emulsions rich in 
ω-6 fatty acids generally enhance proinflammatory pathways, 
while those containing ω-3 fatty acids are anti-inflammatory. 
Importantly, the high linoleic acid content of soy oil emulsions 
may compete with ω-3 precursors to decrease production of 
the bioactive ω-3 fatty acids, EPA and DHA.
In addition to being anti-inflammatory, ω-3-rich triglycer-
ide emulsions have different pathways of clearance from blood 
compared with ω-6 soy oil emulsions. While ω-6 emulsions 
utilize clearance pathways of lipoprotein lipase, the LDL 
receptor, and apolipoprotein E dependent pathways, ω-3 emul-
sion clearance is much less dependent on these pathways 
resulting in ω-3 emulsion clearance from blood by whole par-
ticle uptake into cells. EPA and DHA also generally increase 
expression of genes and proteins that enhance lipid metabo-
lism, while they generally suppress proinflammatory genes 
and protein levels. With ω-3 fatty acids having important roles 
in cardiovascular outcomes (eg, decreasing arrhythmias), 
enhancing cognitive development and learning, improving 
visual development, controlling adverse immune inflamma-
tory responses, reducing PN liver disease, and their “favor-
able” effects on gene expression, we predict that ω-3 fatty 
acids will have key roles in intravenous feeding.
It is expected that in the future, specific emulsions will be 
indicated for specific types of patients such as low-birth-weight 
infants and patients with inflammatory bowel disease, severe 
trauma, surgical responses, PN-related liver disease, and acute 
events such as stroke. Changing intravenous emulsion fatty 
acid compositions and mixing ratios might also allow specific 
emulsion targeting to specific tissues where they might have 
optimal effects for the different clinical challenges that will 
benefit from intravenous lipid emulsions.
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Indications for Different Populations in 
Different Clinical Settings
Yvon A. Carpentier
The first well-tolerated intravenous (IV) lipid preparation was 
made of soybean triglycerides (TG) emulsified with egg-yolk 
phospholipids. Its use started in Europe in the 1960s and 
allowed reduction of the high glucose load provided in the 
hypercaloric parenteral nutrition; this substantially lowered 
hyperalimentation-associated complications, namely in hyper-
metabolic patients. However, concerns were raised about the 
high ω-6 fatty acid (FA) content of soybean oil, particularly in 
intensive care unit (ICU) patients.
Second-generation lipid emulsions aim at reducing the ω-6 
FA intake by substituting soybean with MCT and/or olive oil or 
by producing structured lipids (combining medium- and long-
chain FA on the same glycerol molecule). These preparations 
help maintain a more balanced FA pattern in plasma and cell 
phospholipids, even over prolonged administration; in addi-
tion, they reduce the risk of peroxidative stress.
The concept of metabolic support (which focuses not only 
on calories and nitrogen, but on the pharmacological properties 
of some nutrients and other mediators) was developed in the 
1990s and can be summarized as decrease quantity, increase 
quality. ω-3 FA can be considered as metabolic mediators; in 
addition, their concentration in cell membranes tends to 
decrease in many populations, since dietary intake of ω-3 FA is 
reduced while that of ω-6 FA has markedly increased.
Among the more recent emulsions, one is exclusively made 
of fish oil TG and has raised particular interest in infant and 
children PN. This is the focus of other presentations. Other 
preparations contain mixtures of fish oil, together with MCT, 
soybean oil, and also olive oil in one emulsion. Infusion of 
such preparations in people are associated with a rapid ω-3 FA 
incorporation in the membranes of important blood cells (WBC 
and platelets).
A number of studies are reported, which evaluate the effect 
of ω-3 FA enriched preparations, particularly in hypermeta-
bolic (ICU and/or surgical) patients. In ICU patients, recent 
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meta-analyses consistently indicate a reduction of ICU and 
hospital stay in patients infused with ω-3 FA-containing prepa-
rations. Reductions of inflammatory responses, improvements 
in gas exchange (with decreased requirement for ventilation), 
and maintenance of liver function are also noted; still, if a trend 
toward reduced mortality is often reported, this does not yet 
reach statistical significance.
Surgical patients also appear to benefit from infusions of 
ω-3 FA enriched emulsions, with a decrease of ICU and hospi-
tal stay, reduced inflammatory reactions, preservation of 
immune response, and less infections and maintenance of 
endothelial and liver functions. Starting ω-3 delivery prior to 
the operation may prove beneficial. Recent research focuses on 
short-term infusions and administration of new preparations.
As a general rule, IV lipid emulsions should not be infused 
too rapidly. Rates in the range of 0.10–0.15 g of triglyceride 
per kilogram of body weight per hour (TG/kg bw·h) are gener-
ally appropriate. Special caution is required in subjects with 
high basal serum TG concentrations (>2–4 mmol/L or 170–350 
mg/dL). TG levels should be monitored during (the first days 
of) infusions and infusion rate altered as needed, not to exceed 
values of 4–5 mmol/L (or 350–440 mg/dL).
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Clinical Issues With Dosing of Currently 
Available U.S. Therapy
Steven A. Abrams
Who receives IV lipids in the United States? 1) Very low birth 
weight (<1500 g) infants totaling about 55,000 each year in the 
United States (1.4% of births); 2) Infants with congenital 
bowel abnormalities or intestinal perforations; 3) Infants with 
infections/sepsis or necrotizing enterocolitis (NEC); 4) Infants 
with other major health issues, most notably congenital heart 
disease.
Generally, NICUs provide 3 g/kg/d of lipids as part of full 
PN. The most obvious reason for this is to maintain the per-
centage of calories from fat below 40%–50% to match breast 
milk ratios. Targeted triglyceride levels are variable and most 
NICUs accept <180–250 mg/dL although some target 150–180 
mg/dL. Usually lipids are provided in the United States as 20% 
soybean IVFE. When an infant receives more than about 70 
mL/kg/d of feeds, the percentage of calories from fat will 
exceed 50%. Generally we stop lipids at 80 mL/kg/d of feeds, 
with some exceptions in intestinal failure patients.
Lipid lowering in early cholestasis appears to benefit some 
infants. Clear data about this are lacking. Some do not respond, 
but how many “respond” depends on the definition of response 
and use of ω-3 fatty acid lipid emulsion at any given center. PN 
component shortages are a major struggle of long-term care at 
the present time for PN-dependent infants and may affect our 
perspective on lipid use and outcomes.
The current approach to management of intestinal failure in 
infants is to target growth as essential to a good outcome in this 
high-risk population. Thus, any nutritional approach must 
include a bioavailable source of intravenous fat. Limited enteral 
feeds do not meet this need in many infants. The population of 
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infants needing lipids is mixed and their nutritional needs are not 
the same, nor are there well-tested ideal products available in the 
United States to meet enteral or parenteral needs of this group.
Historical Overview of Endpoints Used 
for U.S. Approvals of Soy-Based IVFE 
Products
Intralipid® Approval in the United States
Staffan Bark
The first parenteral lipid emulsion used on the market in the 
United States was Lipomul® in 1956. It was based on cotton-
seed oil and consisted of mainly 45% linoleic acid, 30% oleic 
acid, and 20% palmitic acid with ω-6/ω-3 ratio of 54:1. Three 
European brands were also developed. The main problems 
with these emulsions were the severe side effects on the liver, 
and general intolerance made it impossible to use for more than 
short periods.
When a new product enters the market, efficacy and safety 
are always key concerns. Due to the problems with Lipomul®, 
Professor Arvid Wretlind and colleagues at Karolinska 
Institute, Stockholm, Sweden, started early to look for alterna-
tives and conducted a long series of experiments in both ani-
mals and humans. They tested many different combinations of 
raw materials and emulsifiers. It was found that soybean oil 
emulsified by egg phospholipids (Intralipid®) was well toler-
ated compared with other emulsions. Intralipid® became avail-
able in Europe in 1962. Lipomul® was finally withdrawn from 
the U.S. market in 1965.
The U.S. Army (and Surgeon General) had for a long time 
looked for a safe lipid emulsion. Their research was behind 
the development of Lipomul®. They were immediately inter-
ested in the development of Intralipid® and a collaboration 
was established with Professor Wretlind. It took 13 years 
after European approval before Intralipid 10%® was 
approved by the FDA in 1975. Meanwhile, numerous single 
patient INDs were used to provide American patients with 
IV lipids when necessary. The first NDA (17-643 Intralipid 
10%®) contains many reports from investigators. These 
reports were only observational, including only single or a 
few cases. They were all in adults and children under the age 
of 4 years. Adolescents were never studied. A survey of the 
parameters in the NDA reveals that they are exactly the same 
variables that we are following today, as summarized in 
Table 2.
NDA 18-449 for Intralipid 20%® was sent to the FDA in 
January 1980. However, the FDA requested to have data 
from the research by the U.S. Army done in the early 1960s 
with Intralipid® 20%. The U.S. Army also sponsored a study 
in Stockholm together with Arvid Wretlind, investigating 
biopsies from livers and spleens after infusions of Intralipid®. 
All these data were included in the Amended NDA in 
November 1980. During the period in between, the investi-
gators of what can be called the pivotal studies continued to 
recruit patients to their studies. The largest study at the time 
ended up with 54 patients and compared safety of Intralipid 
20%® vs Intralipid 10%®. The NDA for Intralipid 20%® also 
included many small studies without any clear statistical 
planning and mainly observational collection of laboratory 
data. Similar efficacy for both formulations of Intralipid® 
was demonstrated in many studies. The pediatric studies also 
showed efficacy by increased body weight, length, and head 
circumference, which all are standard parameters to follow 
in this patient group. The laboratory safety data were the 
Table 2. Variables Studied for FDA Approval.
Safety Intralipid® 10% or 20% Efficacy Intralipid® 10% or 20%
Parameter Frequency Parameter Frequency
Triglycerides Almost all studies Albumin/total protein Some studies
Livera Body weight Pediatric studies









Free fatty acids A few studies  
aLiver, in the Safety column, includes total bilirubin, alkaline phosphatases, transaminases, and a few observations with bromsulphthalein test (BSP).
bIntralipid® 20%.
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same as for Intralipid 10%®, and the table above applies also 
to the studies with Intralipid 20%®. However, additional 
observations of nitrogen balance were performed both in 
pediatric and adult patients.
Laboratory safety data were collected for both NDAs. 
Safety with respect to the impact on the liver was a main con-
cern. Adults and the youngest children were studied. Efficacy 
was shown in some studies by registration of cumulative nitro-
gen balance and albumin/protein levels. Growth and body 
weight were registered in pediatric studies.
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Liposyn® products were developed under Abbott Laboratories 
Hospital Products Division. Hospira spun off from Abbott 
Laboratories in May 2004. Products included Liposyn 10%® 
and 20%®, which were composed of 100% safflower oil, 
Liposyn II® 10% and 20% (50/50 soybean/safflower oil), and 
Liposyn III 10%, 20%, and 30% (100% soybean oil). The 
30% Liposyn III is in a pharmacy bulk package for 
admixing.
The original Liposyn® formulation has a fatty acid compo-
sition of 77% linoleic and 0.1% linolenic. It was approved in 
May 1979 (10%) and October 1981 (20%). When Liposyn II® 
was approved in 1984, Liposyn® was discontinued and the 
NDA has been withdrawn. Clinical trials in Liposyn® were 
conducted in adult and pediatric patients. Triene/tetraene ratio 
was used to evaluate efficacy in phase II/III trials for Liposyn 
10%®.
Liposyn II® was developed to increase the linolenic acid 
content. The fatty acid composition was 65.8% linoleic and 
4.2% linolenic. Trials included a pediatric study comparing the 
original Liposyn® formulation with Liposyn II® and a com-
parative study of lipid clearance rate between Liposyn®, 
Liposyn II®, and Intralipid™®. Liposyn II® was approved in 
August 1984. A pediatric phase IV trial in neonates was com-
pleted in 1987.
Liposyn III® was approved in September 1984, based on 
literature. The composition is linoleic acid 54.5% and linole-
nic acid 8.3%. Liposyn III® 30% was studied in 20 adult post-
surgical or medical patients. The dose was 1 g/kg/d over 
10 hours given by direct infusion. Triglycerides, free fatty 
acids, and cholesterol were evaluated up to 24 hours after the 
start of the infusion. Liposyn III® 30% was approved in 
January 1998.
International Products: Description of 
Key Clinical Trials Submitted for Drug 
Approval in Other Countries
Lipoplus® Product Development (B. Braun)
Elke von Kleist
“First generation” lipid emulsions were developed to provide 
essential fatty acids (FA), namely ω-6 FA for parenteral nutri-
tion (PN). Vegetable oils (eg, soybean oil), which are rich in 
these essential FAs, were chosen. In addition, the lipid emul-
sions also provided an alternative source of energy to reduce 
excessive glucose administration within a “total PN” regi-
men. Later, it was recognized that these lipid emulsions were 
associated with negative effects on the immune function, due 
to proinflammatory metabolites of the ω-6 FA. Thus, the 
development of lipid emulsions with a reduced amount of 
ω-6 FA was aimed at. In the “second generation” of lipid 
emulsions, soybean oil was partly replaced by immunologi-
cally neutral fat such as medium-chain triglycerides (MCTs) 
from coconut oil. MCTs are more easily hydrolyzed, the 
resulting medium-chain FAs are more readily oxidized than 
long-chain FAs, and the transport into the mitochondria is 
carnitine independent.
Lipoplus® belongs to the “third generation” lipid emulsion 
products. Based on the well-known use of the “second genera-
tion,” a further reduction of ω-6 FA by ω-3 FA derived from fish 
oil was intended. The aim was to provide an alternative lipid 
emulsion for parenteral nutrition calorically equivalent to avail-
able lipid emulsions (first and second generation), but balanc-
ing essential FAs of both the ω-6 series and of the ω-3 series. 
The latter are provided as biologically active forms (eicosapen-
taenoic acid [EPA] and docosahexaenoic acid [DHA]), recog-
nizing scientific knowledge of the FA metabolism.
Three “key” clinical trials that were used for registration 
purposes are presented. Lipoplus® was used in abdominal 
surgery patients and in patients on mechanical ventilation, 
respectively, requiring total PN. Duration of treatment lasted 
from 1 day up to 13 days, mostly for 5 days. FA pattern, for 
example, incorporation of EPA and DHA into phospholipids, 
or the nonprotein respiratory quotient were used as primary 
efficacy endpoints. The incidence of adverse events was 
chosen for primary safety assessment. Explorative analyses 
were performed on the capacity to form leukotrienes from 
ω-3 FA incorporated into leukocyte membranes (efficacy) 
and on various clinical chemistry and hematology variables 
(safety).
Altogether, various phase II studies as well as two phase III 
studies were performed. Overall, 408 patients received this 
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third generation lipid emulsion consisting of soybean oil, 




CLINOLEIC® is a lipid emulsion for intravenous infusion 
indicated as a source of calories and essential fatty acids (EFA). 
In the United States, the product is called Clinolipid®, and the 
approved indication is for adults. It is not indicated for use in 
pediatric patients in the United States because there are insuf-
ficient data to demonstrate that Clinolipid® provides sufficient 
amounts of essential fatty acids in this population. In addition, 
the indication in the United States includes a “Limitation of 
Use” statement that states that the ω-3:ω-6 fatty acid ratio in 
Clinolipid® has not been shown to improve clinical outcomes 
compared with other intravenous lipid emulsions. 
CLINOLEIC® is comprised of a mixture of refined olive oil 
and refined soybean oil in an approximate ratio of 4:1 
(olive:soy). The content of essential fatty acids (linoleic plus 
α-linolenic acid) in the finished product is 20% of the total 
fatty acids. CLINOLEIC® was first approved by the Mutual 
Recognition Procedure (MRP) with France as the Reference 
Member State in 1995 and has subsequently been approved in 
51 countries (approved in 49 countries for pediatric patients) 
with approximately 55 million doses given.
CLINOLEIC® was developed to provide an intravenous 
lipid emulsion having a lower proportion of polyunsaturated 
fatty acids, while still providing an adequate amount of essen-
tial fatty acids to prevent and correct essential fatty acid defi-
ciency in adult and pediatric patients requiring parenteral 
nutrition. CLINOLEIC® was formulated with a lower soybean 
oil content than currently marketed emulsions in order to 
reduce linoleic acid levels. However, CLINOLEIC® contains 
the same 5 major fatty acids, including the same EFA compo-
nents (although different percentages of fatty acids) as the ref-
erence listed drug, INTRALIPID®. The original CLINOLEIC® 
dossier relied on Baxter’s clinical and nonclinical data compar-
ing CLINOLEIC® to INTRALIPID®, to support the safety and 
efficacy of the CLINOLEIC® product.
For the original MRP submission, the registration included 
a complete preclinical development section and 15 clinical 
studies in humans (n = 265 adults, n = 39 pediatric). Of these 
studies, 44 were pharmacological studies in healthy volun-
teers, 8 were safety and efficacy studies in adult patients, and 3 
were safety and efficacy studies in pediatric patients. Primary 
and secondary endpoints for these trials were varied, including 
anthropometric measures and biomarkers of lipid and protein 
metabolism. Registrations in most other countries (ie, Australia, 
Latin America, and Asia) used the information from the 
European registration, with the most recent approval in Canada 
in 2010. For global expansion, an additional trial was com-
pleted in 200 patients. The primary endpoint for this 
noninferiority study was albumin. Prealbumin, lipid metabo-
lites, and body weight were used as secondary end points.
The most recent approval occurred in the United States on 
October 3, 2013 (CLINOLEIC® name changed to 
CLINOLIPID®). The New Drug Application (NDA) included 
clinical studies enrolling a total of 386 adult and 198 pediatric 
patients treated with CLINOLEIC® or CLINOLEIC® contain-
ing multichamber products. The NDA submission contained 
the following:
•• 23 Baxter-sponsored efficacy and safety studies:
	 ○  14 studies in adult patients (n = 261 CLINOLEIC®, 
n = 179 INTRALIPID®, n = 69 other lipid)
	 ○  1 study in elderly patients (n = 10 CLINOLEIC®, n 
= 9 treated with enteral feeding)
	 ○  3 studies in pediatric patients (n = 39 CLINOLEIC®, 
n = 39 INTRALIPID®)
	 ○  5 uncontrolled studies:
• •  4 studies in adult patients (n = 115 CLINOLEIC®)
• •   1  study  in  pediatric  patients  (n  =  159 
CLINOLEIC®)
•• Review of published literature: (evaluation of safety, 
efficacy, and exposure):
	 ○  18 adult studies (n = 3539 CLINOLEIC®, n = 357 
soybean oil–based lipid emulsion)
	 ○  14 pediatric studies (n = 298 CLINOLEIC®, n = 
206 soybean oil–based lipid emulsion)
As part of this approval, postmarketing commitments included 
a phytosterol analysis program, a human factor study, and 
additional clinical trials with CLINOLIPID®.
SMOF Product Development in Adults: A 
28-Day Study
Jonathan Shaffer
A randomized double-blind prospective study was performed 
in 11 centers in 7 different countries (Poland, Denmark, France, 
Netherlands, Israel, Australia, and the United Kingdom). It 
compared 28 days of either soybean based (Intralipid®) or soy-
bean, MCT, olive oil, fish oil based (SMOF®) lipid as a part of 
a regime of parenteral nutrition given to stable patients already 
on parenteral nutrition because of intestinal failure. Institutional 
review board approval was achieved in each center. Seventy-
five patients were randomized and 2 patients received no study 
medication, giving an intention to treat a population of 73 (34 
in the SMOF® group and 39 in the Intralipid® group).
The 2 groups were demographically similar except that the 
SMOF® group were older (53.2 vs 45.2 years, P = .02). More 
than 50% of all patients had a diagnosis of short bowel syn-
drome. There were no differences in the exposure to study 
medication or duration of study days. Both groups had compa-
rable daily doses in intravenous lipid [1.3 (±0.3) in the SMOF® 
group and 1.3 (±0.2) g/kg/d in the patients randomized to 
778 Journal of Parenteral and Enteral Nutrition 39(7)
Intralipid®]. There was no difference in biochemical values 
between the 2 groups at the start of the study. While no values 
varied outside the laboratory reference range, the ALT, AST, 
and total bilirubin mean values went up in the Intralipid® group 
and down in the SMOF® group. There were no significant 
changes in the markers of inflammation (CRP, IL6, and sTNF-
RII). The SMOF® group did demonstrate significant increases 
in serum α-tocopherol, eicosapentaenoic acid, and docosa-
hexaenoic acid and a decrease in the ω-6/ω-3 fatty acid ratios, 
while there were no changes in the Intralipid® group.
Author’s experience: I helped set up our adult Home 
Parenteral Nutrition (HPN) program in 1980. The vast majority 
of patients had short bowel syndrome and <5% have had a can-
cer diagnosis. In 1996, I was able to have our hospital recog-
nized as having 1 of 2 national intestinal failure units in England. 
By 2013, we have treated >580 patients, with 20 patients on the 
program for >20 years. In a recent review, we have had 160 
deaths, 134 from the underlying or other diseases and 26 related 
to HPN complications. For the last 5 years our catheter infection 
rate has been 0.25/1000 catheter days. Our patients on average 
require 5 nights of intravenous feed of amino acids, glucose, 
minerals, and vitamins and the majority have 1–2 nights of lipid 
per week. Only a tiny minority are nil by mouth; the vast major-
ity eat, if only for psychological reasons.
At the start of our program, the only lipid option was 
Intralipid®. By the 1990s, with the advent of the newer emul-
sions, we were able to use these new preparations, initially for 
Intralipid® intolerance, but gradually in the majority of new 
home patients. The advent of SMOF® in 2005 gave us an extra 
option. We have found that in 3 of our patients with raised bili-
rubin levels, where we suspected the lipid may have been 
responsible, changing the patient to SMOF® from Intralipid® 
resulted in an improvement in their blood parameters. We are 
now using SMOF® in nearly all our new HPN patients.
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Omegaven and SMOFlipid Product 
Development
Denis Bonnot
From the wide use of Intralipid® and other 100% soybean oil–
based fat emulsions, there has been the emergence of cholesta-
sis associated with prolonged administration. Also raised have 
been concerns with the high content of ω-6 fatty acid (FA) lin-
oleic acid in soybean oil and the resultant high ω-6/ω-3 ratio.
Omegaven®. To widen the array of FAs supplied in fat emul-
sions, Fresenius Kabi first developed a fish oil–based fat 
emulsion, with the ω-3 FAs, EPA, and DHA representing 
approximately 50% of the FAs.
Replacing 10%–20% of the standard fat emulsion with 
Omegaven® results in a more balanced FA supply, with the 
amount of linoleic acid decreasing and the ω-3 FAs increasing 
with a resulting decrease of the ω-6/ω-3 ratio. The supply of 
the essential FAs linoleic acid (ω-6) and alpha-linolenic acid 
(ω-3) remains within the recommended range.
Clinical development included four phase I trials assessing 
tolerance and pharmacokinetics. Five phase II trials were per-
formed in patients with doses ranging from 10% to 20% of 1–2 
g/kg/d of the fat emulsion, given over 1–2 weeks.
In the soybean oil + Omegaven® group, efficacy assessment 
showed a significant increase of EPA and DHA in blood phos-
pholipids and a marked increase of ω-3 series-derived eico-
sanoids versus the soybean oil only group. No safety concerns 
were revealed.1,2
Omegaven® was first registered in 1998 and is currently 
marketed in 39 countries in Europe, Asia, and Latin America, 
with an estimated 870,000 patients having received Omegaven®.
SMOFlipid®. Fresenius Kabi later developed a more balanced 
fat emulsion, SMOFlipid®. Mixing different sources of fatty 
acids (soybean oil 30%, medium-chain triglycerides 30%, 
olive oil 25%, and fish oil 15%) provides a wide array of FAs 
from saturated to polyunsaturated. The supply of essential FAs 
remained within recommendations. Compared with Intra-
lipid®, there is a lower amount of linoleic acid and a higher 
amount of ω-3, thereby decreasing the ω-6/ω-3 ratio.
Clinical development included two phase I trials assessing 
pharmacokinetics. Two phase IIb-III short-term trials in prema-
ture infants, one 4-week phase III study in infants aged 1 month 
to 11 years, two 5-day trials, and one 4-week trial in adults were 
performed comparing SMOFlipid® to soybean oil fat emul-
sions. Treatment dose ranged from 1 to 2 g/kg/d in adults and 
from 0.5 to 2 g/kg/d in infants, up to 3.5 g/kg/d in premature 
infants. Duration of the studies ranged from 5 to 7 days in hos-
pitalized patients up to 4 weeks in patients requiring home PN.
Safety was confirmed as determined on clinical and labora-
tory parameters, which did not reveal differences between the 
groups. Efficacy assessment showed a significant increase in 
EPA and DHA content in blood phospholipids and changes in 
synthetized eicosanoids resulting from the decreased ω-6/ω-3 
ratio. Changes in laboratory nutritional parameters and body 
weight in pediatrics were similar between the study groups, as 
all fatty acids have an equivalent caloric value.3-5 SMOFlipid 
was first registered in 2004 and is currently marketed in 62 
countries in Europe, Asia, Australia, Latin America, and 
Canada, with an estimated 700,000 patients having received 
SMOFlipid®.
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Knowledge Gaps in the Investigation and 
Use of New Parenteral Lipid Emulsions
Bruce R. Bistrian
The identification of knowledge gaps in the investigation and 
subsequent use for new parenteral lipid emulsions in the United 
States is to a large degree speculative and subject to the bias of 
the proposer. With that caveat, 3 of the areas of considerable 
uncertainty in my estimation are as follows:
1. The impact of different lipids and mixtures on the sys-
temic inflammatory response and its implication(s) for 
clinical outcome
2. The effects of baseline nutritional status and criticality 
of illness on response(s) to parenteral lipids
3. The possible revision of maximal infusion rates and 
doses related to novel properties of new lipid 
emulsions
The systemic inflammatory response, particularly as it 
relates to the pathogenesis and treatment of sepsis and septic 
shock, has been recently reviewed1 and in its most simplified 
form is a combination of numerous proinflammatory and anti-
inflammatory components with the former producing potential 
damage to host tissue by collateral injury during its battle with 
pathogens and with the counterinflammatory response causing 
immunosuppression while attempting to contain injury and 
induce repair.1 Therapeutic attempts to influence this process 
by anticytokine therapy and activated protein C have not been 
successful, and immune stimulatory therapies have not been 
tested.1 Different lipids have been extensively shown to influ-
ence the systemic inflammatory response but in a more modest 
manner than anticytokine therapy, and they act particularly 
through down-regulation of proinflammatory cytokine 
response and the production of less proinflammatory and pro-
coagulant eicosanoids as well as more active healing and repair 
through other lipid mediators.2 Thus, it is difficult to predict 
but unlikely that in a heterogeneous population of critically ill, 
changes in lipid type would affect mortality rates, which has 
been the principal endpoint used to date in the experimental 
therapies of sepsis and septic shock. Early evidence using fish 
oil as the candidate lipid, which has the greatest impact so far 
on the systemic inflammatory response, has not shown benefit 
for mortality or morbidity3 supporting this contention. 
However, that does not mean there was a less critically ill pop-
ulation to be used, such as following major thoraco-abdominal 
surgery, that improvements in morbidity such as infection rates 
and length of stay might be favorably improved. Such patients 
are common, have high rates of immunosuppression and post-
operative infection and high risk for prolonged stays, and often 
require parenteral nutrition. Preliminary evidence for efficacy 
using these endpoints has been confirmed in a meta-analysis of 
the use of fish oil emulsions.4 This comparison of the effects of 
anticytokine therapy and nutritional lipid administration based 
on the degree of systemic inflammatory response might be 
considered analogous to the lack of effect of anticytokine ther-
apy on mortality in severe systemic inflammation as seen in 
sepsis and septic shock but with substantial improvement in 
morbidity when such therapy is applied chronically in diseases 
like rheumatoid arthritis, psoriasis, and inflammatory bowel 
disease, which have a more modest systemic inflammatory 
response occurring on a chronic basis. Another potential ave-
nue of investigation would be to define a more homogeneous 
group of the critically ill such as those with ARDS where the 
impact of the lipid on eicosanoid production might be particu-
larly effective to improve morbidity. There is substantial pre-
liminary evidence for the beneficial impact of a full enteral 
formula containing a novel mixed lipid in this setting.5 Perhaps 
a study of parenteral feeding with novel lipids would be worth-
while in ARDS, but it would be important to study the lipid as 
a component of a complete nutritional formula, because it has 
been shown that the individual components without full feed-
ing are not effective in ARDS6 as might have been anticipated.7 
A final consideration is the degree of immunosuppression and/
or immunomodulation to be anticipated with several candidate 
lipids. The most proinflammatory are those containing the ω-6 
fatty acid, linoleic acid as the principal component, with 
medium-chain triglycerides being essentially neutral, high 
oleic acid–containing lipids having a modest benefit for 
immune modulation with lipids with a high content of the ω-3 
fatty acids, eicosapentaenoic, and docosahexaenoic acid, hav-
ing the most profound immunomodulatory effect.2 Perhaps 
disease states should be categorized as to whether their adverse 
impacts are due to excessive proinflammation or excessive 
immunosuppression before deciding which lipids to study and 
whether the control arm should be an equal amount of lipid that 
has the contrary effect in order to maximize the difference 
rather than the use of a no lipid control.
For critically ill patients in intensive care units, there has 
been recently demonstrated a clear effect of baseline nutri-
tional status as reflected in the BMI on clinical outcome.8 
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Those with a BMI <18.5 kg/m2 have a dramatically increased 
mortality rate with a paradox in the obese in that the optimal 
BMI for survival is 42.6 kg/m2.8 While it is easy to understand 
why the malnourished with poor energy reserves do not fare 
well, particularly given the inadequate feeding characteristic in 
the critically ill, it is likely that the improved survival of the 
morbidly obese also relates to their energy stores, making them 
able to compensate to a greater degree for inadequate intakes. 
However, this situation may impact feeding regimens as well. 
Obviously in the malnourished at least, energy requirements 
should be provided, and given the adverse impact of excessive 
parenteral glucose in the critically ill,9 parenteral lipids should 
be a component of such feeding. Whether novel lipids pro-
vided to meet full or nearly full energy requirements have 
clinical benefits for this group should be studied separately 
from the obese, where hypocaloric feeding might be appropri-
ate as an alternate feeding strategy. Moreover, the obese and 
the morbidly obese are now a quite sizable group. At least one-
third of Americans are obese, and recent data show a much 
greater increase for the morbidly obese, approaching 6% of the 
population. What should be the role for new parenteral lipids in 
such patients? Preliminary evidence suggests benefits for 
hypocaloric feeding over full feeding to meet energy require-
ments.10 In such a situation, the patient fed a lipid-free regimen 
remains on a mixed-fuel system with the fat burned coming 
from endogenous stores. A number of questions arise. Should 
added lipid to such regimens be hypocaloric in amount? Should 
there be controls of no added lipid along with conventional 
soybean oil? Shouldn’t baseline nutritional status be a determi-
nant for study entry?
A final brief issue entails the limits on dosing of new paren-
teral lipids for study. Because it had been shown that rapid 
infusion rates could on the one hand block reticuloendothelial 
system function and thereby lead to infection, and on the other 
foster excessive production of eicosanoids that reversed 
hypoxic vasoconstriction or increased pulmonary artery pres-
sures, a dose of .11 g/kg/h was identified from these studies 
that did not have these effects.11 Since some of these proposed 
lipids have improved clearance rates12,13 and very different 
effects on eicosanoid production,2 should studies be performed 
to identify these characteristics, even though in clinical study 
rates of infusion might be limited to those that have been estab-
lished as safe for the control infusion, soybean oil?
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Clinical Outcome Measures Based on 
Clinical Benefits Other Than Nutrition/
Calories
Thomas R. Ziegler
IVFEs provide critical energy sources and essential fatty 
acids, both of which are important for cell and organ function, 
immunity, wound healing, and convalescence. The charge of 
this lecture was to discuss the data to support specific end-
points as a clinically meaningful outcome measure or as a sur-
rogate in clinical design of trials to test the safety and efficacy 
of IVFE products. However, earlier clinical trial data on clas-
sic clinical outcome measures due to different IVFEs (eg, 
mortality, infection, length of stay [LOS]) in nutrition support 
research have often not incorporated rigorous study designs. 
There remain major areas of uncertainty in most areas of 
nutrition support in the intensive care unit setting, the hospital 
ward setting, and in patients requiring home PN. PN with 
IVFE (in a total nutrient admixture or given separately) has 
become routine, despite lack of rigorous comparative effec-
tiveness trials of the various modalities. Guidance to date has 
been based largely on expert opinion and on data from obser-
vational and small clinical trials, while limited information on 
alternative substrates from proper randomized controlled tri-
als (RCTs) is available.
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Soybean oil–based IVFEs have been available (and used 
routinely in the United States) for over several decades. 
Alternative IVFEs (soybean oil, fish oil, olive oil, structured 
lipids, combinations [SMOF]) have been used worldwide 
(except in the United States) for many years. No significant 
adverse effects have been reported to date with regard to these 
alternative IVFEs. Soybean oil–based IVFEs are associated 
with cholestasis in infant short bowel syndrome, leading to use 
of lipid restriction and alternative IVFE strategies (eg, IV fish 
oil). In adults, previous concerns of proinflammatory/pro-oxi-
dative stress effects of soy-based IVFEs may have been over-
stated given existing data.
Data to support specific endpoints as a clinically meaning-
ful outcome measure or as a surrogate are lacking, and the sur-
rogate biomarkers in IVFE research have not been linked to 
clinical outcomes. With regard to mortality as an endpoint in 
IVFE nutrition research, advantages are that this endpoint is 
easy to measure and is a gold-standard outcome; disadvantages 
are that patient mortality is a nonspecific for IVFE (or PN) 
intervention because many factors influence it (underlying dis-
eases, age, adequacy of medical/surgical care, etc). Infectious 
complications would be an adequate outcome variable for a 
specific IVFE product, but disadvantages include nonspecific-
ity (as in mortality). In addition, infections need to be validated 
with an infectious disease specialist as they are difficult to 
accurately diagnose in many cases (eg, ventilator-associated 
pneumonia). Time on mechanical ventilation is easy to mea-
sure and could be a good outcome variable if true for a specific 
product, but disadvantages are that this endpoint is nonspecific 
for intervention, as many factors influence it (underlying dis-
eases, age, adequacy of medical/surgical care, etc).
Nutritional support or specific nutrient interventions are 
essential when malnutrition or depletion of a specific nutrient 
is the primary (or a major) contributor to mortality and morbid-
ity. The uncertainty arises around what is a meaningful end-
point when the nutritional treatment is an ancillary, albeit an 
important, intervention (eg, impact of IVFE to support cells, 
organs, wounds, and overall metabolism with substrate, energy, 
and essential fatty acids). The group discussed whether we 
may be setting the bar too high in IVFE research. One signifi-
cant area of uncertainty is the problem that nutritional assess-
ment is currently imprecise, and new methods (eg, 
metabolomics) hold promise to further define biomarkers for 
assessment of individualized nutritional status and response to 
nutritional therapy.
Further discussion of the group centered on what could be 
optimal clinical endpoints (assuming rigorous clinical research 
design features) in future research on IVFEs: 1) Should mortal-
ity, LOS, infections, and time on ventilator be primary or sec-
ondary endpoint, versus being used primarily as safety 
endpoints? 2) Should normalization of low blood levels of a 
nutrient, or stability of a nutrient or metabolic pathway (eg, 
evidenced by stable or improved blood essential fatty acids, 
free fatty acids, triglycerides), be adequate endpoints? 3) Are 
novel study designs needed (eg, single-arm studies with his-
torical controls)? 4) Should composite clinical outcome end-
points be used? 5) Should noninferiority studies be the goal for 
outcome studies of essential nutrients?
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Intravenous Fat Emulsion Safety
Jay M. Mirtallo
Fat emulsions are complex pharmaceutical formulations whose 
infusion affects many different biological processes and organ 
systems. As a formulation, these effects are the result of the oil, 
as well as other components of the preparation. Fat emulsions 
are oil-in-water emulsions using an egg yolk phosphatide as an 
emulsifier. The preparation also contains glycerol for tonicity, 
which allows safe infusion into the vein. Adverse effects are 
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not only the result of the fat (inflammatory effect, predisposi-
tion to lipid peroxidases during storage and use, and phytos-
terol content) used for the emulsion but also the emulsifier 
(clearance of infused fat, allergy, and particle size or stability). 
Soybean oil emulsions have a wide variety of adverse effects 
reported in the literature affecting immune function and coagu-
lation and resulting in hepatobiliary disease, pulmonary com-
promise, and fat overload syndrome. Most of these effects 
could be related to exceeding the manufacturer’s recommended 
dose or administering the emulsion at rates in excess of the 
body’s clearance rate.
A few of the adverse event reports correlated these findings 
with hypertriglyceridemia. This led to recommendations to 
withhold, discontinue, or decrease the dose of fat emulsions 
when triglyceride levels were >400 mg/dL for adults and >200 
mg/dL for neonates. This recommendation assumed the elevated 
triglycerides were the result of infused rather than endogenously 
produced triglycerides. The caution for hypertriglyceridemia 
was for the potential to induce pancreatitis in adults and hyper-
lipidemia and fat overload in neonates.
Soybean oil emulsions have immune system effects. The 
effect on the reticuloendothelial system is related to duration 
and infusion rate where effects are minimized by continuous 
infusion (rather than intermittent infusion). The effects on 
immune mediators have been assessed with variable results 
and inconsistent correlation with infectious complications. The 
direct effect of intravenous fat emulsions on infections is due 
to the in-use contamination of the product by Malassezia fur-
fur. Immune effects of one study associated with decrease in 
LOS in the ICU and hospital are responsible for the guideline 
recommendation to withhold fat emulsions for the first 7 days 
of parenteral nutrition therapy in critically ill patients.
The pulmonary effects of soybean oil emulsions are depen-
dent on the rate of infusion and disease condition. 
Hyperlipidemia is associated with alveolar diffusion difficul-
ties. Short-term (4 hours) fat infusions increase triglyceride 
levels in patients with pulmonary disease. There is no signifi-
cant effect of hypertriglyceridemia on those with pneumonia or 
COPD. But a significant decrease in Pao
2
 as well as increased 
intrapulmonary shunting was found in ARDS patients, effects 
of which were reduced by slowing the infusion rate. Infusion 
rate of fat emulsions influences pulmonary vasculature with 
fast infusions, causing vasoconstriction and slow infusions 
resulting in vasodilatation.
Parenteral nutrition–associated liver disease is a serious com-
plication of parenteral nutrition in children and adults receiving 
long-term PN. Prevalence of PNALD in adults increases with 
duration of PN: 55% at 2 years, 64% at 4 years, and 72% at 6 
years. The role of fat emulsions in the development of PNALD 
could be related to the fat source, phytosterol content, and the 
dose. Phytosterols are inefficiently metabolized to bile acids by 
the liver and may impair bile flow. Phytosterol levels are 
increased in short bowel patients receiving soybean oil emul-
sions. The dose of fat emulsion >1 g/kg/d in patients receiving 
long-term PN is associated with chronic cholestasis and severe 
PNALD. Cholestatic jaundice in long-term adult PN patients 
resulting from high doses of fat emulsions was instrumental in 
defining the maximum daily dose at 2.5 g/kg/d.
New fat emulsions may improve the safety of fat emulsion 
use in PN in a variety of ways. For soy-allergic patients it could 
provide a source of essential fatty acids. With improved stabil-
ity, the fat particle size could be maintained over longer peri-
ods under various conditions of storage and transportation. 
Formulations with monounsaturated fat and/or including anti-
oxidants that counteract lipid peroxidases reduce this potential. 
New fat formulations may also test the limits of dose, rate of 
infusion, and duration of safe therapy that now exist for soy-
bean fat emulsion.
A final consideration in safety is the system by which it is 
delivered to the patient. Medication errors occur with fat infu-
sions separately infused from PN, usually at the administration 
node. The cause is related to misinterpretation of the order or 
improper programming of the infusion pump. The lack of a 
standard method of ordering fat emulsions is a continual prob-
lem in clinical practice.
Complications of intravenous fat emulsions are often 
related to the dose, infusion rate, and particle size of the emul-
sion, the incidence and consequences of which may be mini-
mized by following recommended dosing guidelines. PNALD 
is a serious disorder that may warrant cautious use of soybean 
oil fat emulsion in long-term PN patients. Elevated triglyceride 
levels are a frequent reason to decrease or discontinue fat 
emulsion therapy. New fat emulsions have the potential to 
resolve some of the safety issues of soybean emulsions.
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Strengths and Limitations of Biochemical 
Markers and Diagnosis of Essential Fatty 
Acid Deficiency
J. Thomas Brenna
Dietary essential fatty acids (EFAs) are required nutrients 
because they cannot be biosynthesized de novo from general 
carbon sources such as acetate by humans. The 2 families of 
EFAs are defined by their biochemical structures and are 
known as ω-6 and ω-3. The principle dietary parent fatty acids 
were studied starting in the 1950s1 and established that ω-6 
linoleic acid (LA, 18:2ω-6) prevented the major clinical symp-
tom of EFA deficiency (EFAD), scaly skin, and attendant poly-
dipsia due to the compromised water barrier.2,3 Later work 
clearly established that the ω-3 alpha-linolenic acid (ALA, 
18:3ω-3) is the analogous ω-3 parent fatty acid. Detailed bio-
chemical studies showed that both LA and ALA are precursors 
for the long-chain polyunsaturated fatty acids (PUFAs), ω-6 
arachidonic acid (AA or ARA, 20:4ω-6), and ω-3 eicosapen-
taenoic acid (EPA, 20:5ω-3), and ω-3 docosahexaenoic acid 
(DHA, 22:6ω-3), which are further converted to eicosanoids 
and docosanoids and also are required for structural integrity 
of the brain, retina, and neural tissue. Accordingly, LA and 
ALA are metabolically essential primarily as precursors for 
long-chain PUFAs rather than for functions specific to LA and 
ALA themselves. Importantly, AA, EPA, and DHA are all 
available from dietary animal foods, specifically meats and 
seafood, whereas, with rare exceptions, vegetable sources con-
tain only LA and ALA.
The main biochemical marker for EFAD is Mead acid, an 
ω-9 fatty acid that is structurally the most similar PUFA that 
can be synthesized de novo from acetate or metabolism of 
oleic acid. Mead acid (20:3ω-9) is nontoxic, and its normally 
low level in plasma phospholipids rises significantly when 
PUFAs are not available to replace AA. The triene/tetraene 
ratio developed in the 1960s for ω-6 deficiency is measured in 
plasma phospholipids as the ratio of Mead acid to ARA; a 
value of [20:3ω-9]/[20:4ω-6] >0.4 indicates EFAD. Fat-free 
IV infusions of the 1975s caused a rapid increase of this 
parameter, especially for continuous infusion.4 Importantly, 
Mead acid is synthesized specifically in response to low LA.5 
Neither the growth rate of young animals nor Mead acid rise 
is a good marker for ω-3 deficiency. A rise in ω-6 docosapen-
taenoic acid (DPA, 22:5ω-6), the ω-6 structural analog of ω-3 
DHA, is a more reliable marker for excess ω-6 LA and defi-
cient ω-3,6 although there are no norms for this parameter and 
measurements have not been standardized to diagnosis. 
Accordingly, no good short-term markers are currently avail-
able for low ω-3 levels.
The systematic responses of plasma phospholipids to 
dietary fat and, by implication, IV fat were worked out with 
animals in the 1960s with continuing work through the present 
decade, clarifying various details. LA and ALA are PUFA/EFA 
components of conventional injectable emulsions; thus, details 
of their conversion to active long-chain PUFAs are of most 
importance. In general, and somewhat surprisingly, low total 
PUFA, <2% of total fatty acids, combined with a balance of LA 
and ALA militate to provide maximal synthesis of long-chain 
PUFAs.7 Apart from this, inclusion of preformed EPA and 
DHA would obviate concerns about adequate ω-3 synthesis. 
Current evidence strongly suggests that infants consuming pre-
formed DHA have more rapid brain and visual development 
than those who rely on LA and ALA for all long-chain PUFAs.8
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Impact of Emulsion Components and 
Populations on Endpoints Selected
Berthold Koletzko
What we basically want from parenteral nutrition (PN) is a safe 
supply of energy and nutrients. In pediatrics, you can measure 
that by normal growth and normal development. We can also 
measure that by metabolic and endocrine response using blood 
lipids, lipoproteins, fatty acids, markers of oxidation, antioxi-
dant status, phytosterols, glucose, insulin, and other markers. 
As we break down various types of lipids, we know that the 
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structure will change the energy supply. While medium-chain 
triglycerides (MCTs) have about 16% less chemical energy 
than long-chain lipids (LCTs), this is relatively a small differ-
ence. Importantly, we know that MCTs are very rapidly trans-
ported into mitochondria and rapidly oxidized, far more rapidly 
than LCTs. If you provide lipid emulsions with MCT/LCT and 
compare them with soybean emulsion, the MCT/LCT lipids 
lead to higher oxygen consumption in the immediate period 
after infusion. In other words, a higher thermogenic effect is 
found with MCTs. In addition, energy extraction does not only 
depend on chain length, but varies with different types of fatty 
acids that exchange oxidation. For example, alpha-linolenic 
acid is oxidized to CO
2
 to a far greater extent than linolenic 
acid in humans, and this may affect body composition.
All commercially available lipid emulsions provide enough 
essential fatty acids to effectively prevent linolenic deficiency. 
The only caveat is the 100% marine oil lipid emulsion, and I 
don’t think we have the data to conclude these would be safe in 
providing adequate essential fatty acids if given as a sole 
source of lipids over a prolonged period of time. MCT is the 
preferred substrate for oxidation, leading to better incorpora-
tion of ω-3 and ω-6 fatty acids into plasma lipids. From a pedi-
atric point of view, the perinatal period is one of rapid brain 
growth and development. The brain incorporates a consider-
able amount of DHA as well as arachidonic acid from 25 weeks 
gestation onward to term births and on to about 2 years of age.
As one looks at the composition of soybean oil IVFE 
(SOFE), while they provide a lot of essential fatty acids, they 
are very different from what we eat and from what is in human 
breast milk. We are concerned about this provision of high 
PUFA amounts with SOFE because this high level of PUFA, 
largely above metabolic needs, is suppressing conversion to 
LCTs, which are relevant from a biological effect. SOFE does 
not provide any appreciable amounts of long-chain ω-3 fatty 
acids, and thus there is high risk of toxic peroxidation actions. 
As well, provision of SOFE leads to markedly high levels of 
linolenic acid that you would not see in a fetus or a preterm 
infant who receives human milk. If we provide, instead, an 
olive oil/soy combination, there is still an increase of linolenic 
acid but far less than in the SOFE group. So with the olive oil/
soy combination we have a pattern that was much more similar 
to human milk–fed infants, and we do not see any signs of 
EFAD.
DHA provision to preterms has been highly spoken of in 
recent years. Perhaps the most impressive set of data come 
from a randomized trial in a small number of preterm infants 
from Australia who were randomized to standard DHA dose 
versus high DHA dose. At 18 months, there is a benefit on 
development in girls but not boys. However, more importantly, 
the rate of severe mental retardation is reduced to one-half with 
the higher amount of DHA. So there is a trend in neonatology 
to provide more DHA, which is easy to achieve enterally but 
difficult to achieve parenterally. Studies that provide marine oil 
lipid emulsions in infants have led to increased eicosapentae-
noic acid, but little or modest effects on DHA. Meta-analysis 
of lipid emulsions with marine oils did not show changes in 
mortality in surgical adult patients. However, this meta-analy-
sis showed a near 50% reduction in rate only of infections and 
a significant reduction of length of stay. All of this would trans-
late into huge economic savings. When looking at the very low 
birth weight population, a meta-analysis comparing new ver-
sus old IVFE showed a significant effect: a 25% lower sepsis 
rate with new emulsions. This 25% lower sepsis rate makes it 
very difficult for us now to use a soybean oil emulsion in very 
low birth rate infants.
With regard to parenteral nutrition–associated cholestasis 
(PNAC), we feel strongly that if you prevent catheter infection, 
you can prevent most of these cases. The exciting data from 
Boston show that with the use of 100% marine oil at a low 
dose, there was resolution of PNAC in almost half of the 
patients. Interestingly, very similar results were reported previ-
ously from the group in Paris without marine lipids, but with a 
temporary cessation of SOFE. So, it is important to ask, is it 
really the marine oil that does the trick, or what is the precise 
mechanism leading to PNAC resolution? Potentially, this could 
be due to the antioxidant protection through ω-3 fatty acid. We 
feel this needs to be evaluated further.
In terms of what populations should be studied, clearly sur-
gical patients are a prime candidate. In infants and children, we 
are particularly interested in the preterms and the critically ill 
ICU patients, and that would include surgical infants. An addi-
tional group would be children on long-term home PN. Another 
question is of ethnic and genetic subgroups. To my knowledge, 
this has not been very much considered so far. This is a ques-
tion that is particularly relevant for the United States, because 
we know that African Americans differ in their genotype for 
fatty acid metabolism. They have predominantly a genotype of 
the fatty acid that desaturates with fast PUFA conversion. Such 
variation has been hypothesized as one of the reasons why 
there is such a difference in cardiovascular disease risk between 
Caucasians and African Americans. In terms of outcome mea-
sures, development of weight is a good measure, as are body 
composition, energy intake, and expenditure. Additional clini-
cal endpoints include length of ICU stay, infections, respira-
tory function, ventilation days, and mortality.
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Clinical Issues in Designing a Trial of IV 
Lipids With Currently Available Products in 
the United States
Steven A. Abrams
Challenges and opportunities exist for conducting clinical 
research in infants and children related to novel intravenous 
fatty emulsions (IVFEs). It is important to identify these pedi-
atric-specific issues to enhance the development and investiga-
tion of new products for use in the United States.
A key issue is to determine what population group will be the 
subjects of any investigations. It is likely that the majority of 
infants receiving IVFEs are very low birth weight (VLBW) 
infants. Many current feeding protocols for healthy VBLW 
infants, such as the “Guidelines for Acute Care of the Neonate”1 
from Baylor College of Medicine, recommend stopping IVFE by 
about 1 week of life in otherwise healthy VLBW infants. Thus, 
research in this group would generally be short term and might not 
fully reflect either safety or efficacy of the products being tested.
Another group that might be studied are infants at risk for 
needing long-term intravenous nutrition. This group consists 
of infants with congenital bowel wall defects such as gastros-
chisis and omphalocele, infants with intestinal atresia or abnor-
malities such as Hirschsprung’s disease, and infants born with 
a normal intestine but who suffered an injury to it such as a 
perforation or necrotizing enterocolitis.
Current neonatal intensive care (NICU) practice includes 
limitation in the length of time that arterial and central venous 
access lines are maintained. Furthermore, phlebotomy is lim-
ited in this group. Usually, a maximum of 2–3 mL/kg/d of 
blood can be withdrawn for research purposes at one time and 
6–8 mL/kg/d over longer periods of time. In infants who are 
<1.0 kg, this is a very tight limitation and may restrict research-
related testing.2 Families will not consent to research that 
requires multiple blood draws without a clear benefit to their 
infant. Most laboratory tests performed for research need to be 
those that are required for routine medical care, such as serum 
triglycerides and glucose.
Families, physicians, and institutional review boards are 
generally supportive of nutrition research in the NICU setting. 
They understand that virtually all products used in high-risk 
infants were at one time evaluated in clinical research proto-
cols. There are a number of large centers that care for a consid-
erable number of such high-risk infants on a daily basis and are 
experienced in conducting such research.
IVFEs are often started in high-risk infants within hours of 
birth. Therefore, recruitment and consent must be done before 
birth or very soon after delivery if randomization is to be done 
before receiving any IVFE. Infants transferred from commu-
nity hospitals to large children’s hospitals often have had IVFE 
already started.
The ability of parents to provide meaningful research con-
sent around the time of birth of a sick or small infant is uncer-
tain. Full disclosure of possible risks of involvement in research 
is needed. Medical care teams available outside of weekday 
work hours may not be able to do this well. Trainees may not 
be fully aware of the risk-benefit ratio of the research study and 
may not be ideal for obtaining consent at off hours.
However, many high-risk mothers are admitted >24 hours 
before delivery. Antepartum or prenatal visits are often ideal 
times to approach families and discuss research protocols. The 
primary research team can do consenting then. Most lipid 
emulsions to be tested have extensive history of research and 
clinical use outside of the United States, providing a basis for 
discussions and consideration of the risk-benefit of participa-
tion in the research. One possibility to improve subject recruit-
ment is to allow up to 24 hours of “standard lipid” prior to 
intervention in a protocol.
Neonatologists are interested in the safety of providing a 
full dose of IVFE to their patients (usually 3 g/kg/d) and the 
effects of any novel product on liver function tests, serum tri-
glyceride levels, and growth. Thus, the primary research out-
comes from studying a new product are therefore likely to be 
growth and measures of tolerance in small infants. Secondary 
outcomes might assess additional biochemical findings as is 
feasible. Long-standing unresolved shortages of PN and lipid 
components may be problematic in terms of study design and 
implementation.
In summary, there is a critical need for research into new 
lipid emulsions in the United States. However, study design 
issues are complex and need prereview at multiple levels. It is 
feasible in a multicenter study to compare current IVFEs with 
novel interventions/products and the primary research group 
would be infants at risk for needing long-term PN. How to deal 
with recruitment, phlebotomy, the development of complica-
tions, such as cholestasis, and the use of multicenter consistent 
nutrition protocols are resolvable barriers to implementation of 
these research protocols.
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Intravenous Fat Emulsions—Other Aspects 
of Clinical Trial Design
Gary P. Zaloga
Intravenous lipid emulsions are complex suspensions of tri-
glycerides that contain many different fatty acids with different 
biological actions. The primary goals of administering lipid 
emulsions are the provision of nutrition (ie, energy and essen-
tial fatty acids) and/or treatment of a disease process (ie, thera-
peutic goal). It is the desired product “claim” or “indication” 
that determines the study design. The study may evaluate a 
nutritional or therapeutic claim and may seek superiority or 
noninferiority of the claim versus a standard treatment. In addi-
tion to establishing efficacy of the lipid in supporting the claim, 
clinical studies should also establish safety.
The primary study endpoint should be an outcome variable 
that is directly related to the study product, clinically relevant, 
and easily measurable in a clinical trial. Endpoints are usually 
a biomarker or a patient-specific structural or functional end-
point. Biomarker endpoints must be validated for disease 
development, severity, or progression (including nutritional 
status). In general, there is a lack of validated biomarker end-
points for lipid emulsions. Patient specific endpoints include 
signs and symptoms, patient functions (ie, mobility), adverse 
events, and tissue damage. The most common nutritional end-
points for lipids are the supply of energy (assessed by body 
weight, lean body mass, growth, muscle function) and essen-
tial fatty acids (assessed by fatty acid profiles and the triene-
tetraene ratio). However, there are numerous confounding 
factors that affect these endpoints that include the catabolic 
response to illness or injury, exercise, disuse atrophy (such as 
bed rest), levels of anabolic hormones, comorbid conditions, 
and genetic susceptibility. There are numerous possible physi-
ologic or disease therapeutic endpoints that include treatment 
of cholestasis, postoperative infections, hyperglycemia, 
inflammatory bowel disease activity, and oxygenation in 
patients with pulmonary injuries. In general, therapeutic end-
points should be disease specific and may be studied indepen-
dently of the use of parenteral nutrition. Therapeutic effects of 
lipids may be very difficult to demonstrate due to numerous 
confounding factors.
Most nutritional studies should be randomized, controlled 
(preferably double-blinded) comparative studies. Due to ethi-
cal concerns regarding limiting of nutrition to patients unable 
to consume nutrients enterally, most nutritional studies of 
intravenous lipids compare a new lipid emulsion to a standard 
lipid emulsion. The duration of a study is primarily determined 
by the efficacy and safety endpoints. There must be time to 
demonstrate efficacy via the chosen endpoints. The average 
time for use of parenteral nutrition in hospitalized patients is 
7–10 days, and many patients also receive enteral nutrition 
during this time period. The short time for treatment and lack 
of validated short-term endpoints complicate study of lipid 
emulsions in these patients. One should choose a study popula-
tion that is relevant to use of the lipids as a nutritional agent or 
therapy. The study populations should be chosen and matched 
so as to eliminate as many confounding variables as possible 
and should require the treatment for a duration that is long 
enough to evaluate the study endpoints. The dose of lipid 
should be consistent with the desired effect as a nutritional or 
therapeutic agent and must be demonstrated to be safe. Thus, 
most doses of a nutritional lipid will be administered at 20%–
40% of energy requirements while therapeutic effects may 
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